<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03502681</url>
  </required_header>
  <id_info>
    <org_study_id>BTCRC-GU16-051</org_study_id>
    <nct_id>NCT03502681</nct_id>
  </id_info>
  <brief_title>A Study Combining Eribulin Mesylate With Avelumab in Cisplatin Ineligible Metastatic Urothelial Cell Cancer Patients</brief_title>
  <official_title>Phase 1b Clinical Trial of Eribulin Mesylate and the PD-L1 Monoclonal Antibody, Avelumab, in Cisplatin Ineligible Metastatic Urothelial Cell Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Monika Joshi, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eisai Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Big Ten Cancer Research Consortium</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Big Ten Cancer Research Consortium</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single arm, open-label phase Ib study of combining eribulin mesylate with avelumab.&#xD;
      The initial 9-12 patients (MTD cohort) will be enrolled to determine safety of avelumab in&#xD;
      combination with eribulin mesylate. Upon determination of maximum tolerated dose (MTD), 12&#xD;
      additional patients will be enrolled in an expansion cohort (efficacy cohort) to determine&#xD;
      ORR at 6 months.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Dose Escalation Plan:&#xD;
&#xD;
      A standard &quot;3+3&quot; design will be used to determine the MTD of eribulin with avelumab.&#xD;
&#xD;
      The maximum tolerated dose is the dose of eribulin combined with avelumab with dose limiting&#xD;
      toxicity of 0-1 of 6 patients in the first cycle of combination therapy. After the MTD has&#xD;
      been determined, an additional 12 patients will be enrolled in an expansion cohort at the MTD&#xD;
      to evaluate the efficacy of this combination.&#xD;
&#xD;
      After determination of MTD for eribulin mesylate, an additional 12 patients will be enrolled&#xD;
      on the expansion cohort. Subjects on the expansion cohort will be assessed for adverse events&#xD;
      but will not be assessed for DLTs.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Funder Decision&#xD;
  </why_stopped>
  <start_date type="Actual">June 12, 2018</start_date>
  <completion_date type="Actual">October 25, 2019</completion_date>
  <primary_completion_date type="Actual">October 25, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assess the Adverse Events of Combining Eribulin Mesylate With Avelumab - (MTD Cohort)</measure>
    <time_frame>4-weeks</time_frame>
    <description>Dose limiting toxicities (DLTs) experienced by subjects while being treated with the combination of eribulin+avelumab, by dose level.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assess Response Rates (RR) - (Efficacy Cohort)</measure>
    <time_frame>12 months</time_frame>
    <description>Complete Response (CR) + Partial Response (PR)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess Disease Control Rate (DCR)</measure>
    <time_frame>at 3, 6 months</time_frame>
    <description>Complete Response (CR) + Partial Response (PR) + Stable Disease (SD)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimate Progression Free Survival (PFS)</measure>
    <time_frame>12 months</time_frame>
    <description>probability that a patient remains free of progression of disease by modified RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimate Overall Survival (OS)</measure>
    <time_frame>12 months</time_frame>
    <description>time from start of treatment, Day 1, to the date of death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimate Median Progression Free Survival (PFS)</measure>
    <time_frame>12 months</time_frame>
    <description>measurement from the date of initiation of avelumab+ eribulin, D1 until the criteria for disease progression is met as defined by modified RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimate Median Overall Survival (OS)</measure>
    <time_frame>2.5 years</time_frame>
    <description>time from start of treatment, Day 1, that half of the patients in the group with the disease are still alive.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the Duration of Response</measure>
    <time_frame>2.5 years</time_frame>
    <description>the period measured from the time that measurement criteria are met for complete or partial response (whichever status is recorded first) until the date that recurrent or progressive disease is objectively documented.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Metastatic Urothelial Cell Cancer</condition>
  <arm_group>
    <arm_group_label>Maximum tolerated dose (MTD) cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The initial 9-12 patients (MTD cohort) will be enrolled to determine safety of avelumab in combination with eribulin mesylate.&#xD;
Upon determination of maximum tolerated dose (MTD), 12 additional patients will be enrolled in an expansion cohort (efficacy cohort) to determine objective response rate (ORR) at 6 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eribulin Mesylate</intervention_name>
    <description>Days 1, 15&#xD;
Eribulin mesylate:&#xD;
Dose level -1: 0.7mg/m^2;&#xD;
Dose level 0: 1.1 mg/m^2;&#xD;
Dose level +1: 1.4 mg/m^2</description>
    <arm_group_label>Maximum tolerated dose (MTD) cohort</arm_group_label>
    <other_name>Halaven</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Avelumab</intervention_name>
    <description>Days 1, 15 Avelumab (10mg/kg)</description>
    <arm_group_label>Maximum tolerated dose (MTD) cohort</arm_group_label>
    <other_name>MSB0010718C</other_name>
    <other_name>BAVENCIO</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Subject must meet all of the following applicable inclusion criteria to participate in this&#xD;
        study:&#xD;
&#xD;
          -  Written informed consent and HIPAA authorization for release of personal health&#xD;
             information.&#xD;
&#xD;
          -  Age ≥ 18 years at the time of consent.&#xD;
&#xD;
          -  ECOG Performance Status of 0-2 at the time of enrollment.&#xD;
&#xD;
          -  Life expectancy of &gt;12 weeks.&#xD;
&#xD;
          -  Stage IV patients either locally advanced node positive (these patients must have N3&#xD;
             disease) or metastatic-M1 positive urothelial cancer of bladder and upper tract.&#xD;
&#xD;
          -  Histologically proven urothelial carcinoma of bladder with predominant transitional&#xD;
             cell component. Adenocarcinoma, squamous cell differentiation, or other atypical&#xD;
             histology (such as plasmacytoid or sarcomotoid) of the bladder will be allowed on the&#xD;
             study, provided they form &lt;50% of the histology.&#xD;
&#xD;
          -  Presence of measurable disease per RECIST v1.1 for solid tumors.&#xD;
&#xD;
          -  Patients who are cisplatin ineligible defined by the presence of one or more of the&#xD;
             following:&#xD;
&#xD;
               -  Impaired renal function (GFR ≥ 30 but ≤ 60 cc/min). GFR should be assessed by&#xD;
                  direct measurement (i.e. creatinine clearance or ethylenediaminetetra-acetate)&#xD;
                  or, if not available, by calculation from serum/plasma creatinine by&#xD;
                  Cockroft-Gault equation.&#xD;
&#xD;
               -  Grade ≥ 2 Hearing Loss (hearing loss measured by audiometry of 25 dB at two&#xD;
                  contiguous frequencies)&#xD;
&#xD;
               -  Grade ≥ 2 peripheral neuropathy (Please note that for enrollment on this trial&#xD;
                  patients must have peripheral neuropathy grade 2 or lower)&#xD;
&#xD;
               -  ECOG Performance Status of 2&#xD;
&#xD;
               -  NYHA Class III-IV CHF (Please note that for enrollment on this trial patients&#xD;
                  must have Ejection Fraction of &gt;35% measured on ECHO)&#xD;
&#xD;
          -  Patients must be treatment naïve for metastatic disease. Use of chemotherapy in&#xD;
             neoadjuvant or adjuvant form is allowed provided the time period between last dose of&#xD;
             treatment and enrollment is &gt;12 months and subjects must have recovered from all&#xD;
             reversible toxic effects of the regimen (other than alopecia) to ≤Grade 1 or baseline.&#xD;
&#xD;
          -  Demonstrate adequate organ function as defined below; all screening labs to be&#xD;
             obtained within 28 days prior to study registration:&#xD;
&#xD;
        Hematological:&#xD;
&#xD;
          -  Platelet ≥ 100K/mm^3&#xD;
&#xD;
          -  Absolute Neutrophil Count (ANC) ≥ 1.5 K/mm^3&#xD;
&#xD;
          -  Hemoglobin (Hgb) ≥ 9 g/dL&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Calculated creatinine clearance&#xD;
&#xD;
               -  ≥ 30 cc/min using the Cockcroft-Gault formula (Cockcroft and Gault 1976)&#xD;
&#xD;
               -  or by equivalent criteria such as measured GFR by hospital's laboratory&#xD;
&#xD;
               -  or by 24-hour urine collection for determination of creatinine clearance:&#xD;
&#xD;
        Males:&#xD;
&#xD;
        Creatinine CL (mL/min) = Weight (kg) x (140 - Age) . 72 x serum creatinine (mg/dL)&#xD;
&#xD;
        Females:&#xD;
&#xD;
        Creatinine CL (mL/min) = Weight (kg) x (140 - Age) x 0.85 72 x serum creatinine (mg/dL)&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 × upper limit of normal (ULN)&#xD;
&#xD;
          -  Aspartate aminotransferase (AST) ≤ 2.5 × ULN&#xD;
&#xD;
          -  Alanine aminotransferase (ALT) ≤ 2.5 × ULN&#xD;
&#xD;
        Coagulation:&#xD;
&#xD;
          -  International Normalized Ratio (INR) or Prothrombin Time (PT) Activated Partial&#xD;
             Thromboplastin Time (aPTT) ≤ 1.5× ULN for patients who are not on any anticoagulants.&#xD;
&#xD;
        Patients who are on warfarin would require switching to either a short acting anticoagulant&#xD;
        such as oral apixaban or lovenox injection. Prior to entry on the trial their INR should be&#xD;
        &lt;2.0. Patients who are already on short acting anticoagulants would be allowed to enroll on&#xD;
        the study provided their INR &lt;2.0&#xD;
&#xD;
          -  Females of childbearing potential must have a negative serum or urine pregnancy test&#xD;
             within 7 days prior to registration.&#xD;
&#xD;
          -  Females of childbearing potential and males must be willing to abstain from&#xD;
             heterosexual activity or to use a highly effective method of contraception from the&#xD;
             time of informed consent until 90 days after treatment discontinuation.&#xD;
&#xD;
          -  As determined by the enrolling physician or protocol designee, ability of the subject&#xD;
             to understand and comply with study procedures for the entire length of the study.&#xD;
&#xD;
          -  Availability of baseline tumor tissue (fresh biopsy or archival) prior to enrollment&#xD;
             on the clinical trial. TURBT specimens are preferred but tissue from lymph node or&#xD;
             visceral areas are also acceptable. If archival tissue is not available, the subject&#xD;
             must be willing to consent to a fresh biopsy for research prior to registration for&#xD;
             protocol therapy. If archival tissue is not available and there are no sites amenable&#xD;
             to biopsy, enrollment must be discussed with the sponsor-investigator on a case by&#xD;
             case basis.&#xD;
&#xD;
          -  Palliative radiation therapy prior to or during the treatment is allowed if indicated.&#xD;
             However, if prior to start of treatment, radiation therapy must complete at least 7&#xD;
             days prior to cycle 1 day 1 of treatment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Subjects meeting any of the criteria below may not participate in the study:&#xD;
&#xD;
          -  Participation in another clinical study with an investigational product within 2 weeks&#xD;
             prior to registration.&#xD;
&#xD;
          -  Any previous treatment with a PD1 or PD-L1 inhibitor, including Avelumab.&#xD;
&#xD;
          -  Previous systemic immunotherapy. Previous use of intravesical BCG is acceptable.&#xD;
&#xD;
          -  History of another primary malignancy except for:&#xD;
&#xD;
               -  Malignancy treated with curative intent and with no known active disease ≥5 years&#xD;
                  before the first dose of study drug and of low potential risk for recurrence.&#xD;
                  However adequately treated prostate cancer &gt;3 years ago with no significant&#xD;
                  change in PSA for past 6 months can be included.&#xD;
&#xD;
               -  Adequately treated non-melanoma skin cancer or lentigo maligna without evidence&#xD;
                  of disease.&#xD;
&#xD;
               -  Adequately treated carcinoma in situ without evidence of disease e.g., cervical&#xD;
                  cancer in situ.&#xD;
&#xD;
          -  Receipt of the last dose of anti-cancer therapy for local recurrence only and not for&#xD;
             any systemic disease (immunotherapy, endocrine therapy, biologic therapy, tumor&#xD;
             embolization, monoclonal antibodies, or other investigational agent) within14 days&#xD;
             prior to study registration and within 6 weeks for intravesical BCG or mitomycin C .&#xD;
&#xD;
          -  Mean QT interval corrected for heart rate (QTc) ≥470 ms on electrocardiogram (ECG)&#xD;
             using Frediricia's Correction.&#xD;
&#xD;
          -  Current or prior use of immunosuppressive medication within 28 days before study&#xD;
             registration, with the exceptions of: a) intranasal, inhaled, topical steroids, or&#xD;
             local steroid injection (e.g., intra-articular injection) b) systemic corticosteroids&#xD;
             at physiological doses, which are not to exceed 10 mg/day of prednisone, or an&#xD;
             equivalent corticosteroid, c) steroids as premedication for hypersensitivity reactions&#xD;
             (e.g., CT scan premedication).&#xD;
&#xD;
          -  Any unresolved toxicity (≥CTCAE grade 2) from previous anti-cancer therapy. Subjects&#xD;
             with irreversible toxicity that is not reasonably expected to be exacerbated by the&#xD;
             investigational product may be included (e.g., hearing loss). Alopecia, sensory&#xD;
             neuropathy grade ≤ 2, or other grade ≤ 2 not constituting a safety risk based on&#xD;
             investigator's judgment are acceptable.&#xD;
&#xD;
          -  Active or prior documented autoimmune disease that might deteriorate when receiving an&#xD;
             immuno-stimulatory agent. NOTE: Subjects with diabetes type I, vitiligo, hypo- or&#xD;
             hyperthyroid diseases, or psoriasis not requiring immunosuppressive systemic treatment&#xD;
             are eligible. Patients with a history of completely resolved childhood asthma or atopy&#xD;
             are also eligible.&#xD;
&#xD;
          -  Active or prior documented inflammatory bowel disease (e.g., Crohn's disease,&#xD;
             ulcerative colitis).&#xD;
&#xD;
          -  History of and/or confirmed pneumonitis.&#xD;
&#xD;
          -  History of primary immunodeficiency.&#xD;
&#xD;
          -  History of organ transplantation including allogeneic stem-cell transplant.&#xD;
&#xD;
          -  History of hypersensitivity to Avelumab or Eribulin mesylate, including known severe&#xD;
             hypersensitivity reactions to monoclonal antibodies (Grade ≥ 3).&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including, but not limited to:&#xD;
&#xD;
               -  ongoing or active infection requiring systemic therapy&#xD;
&#xD;
               -  active peptic ulcer disease or gastritis, or active bleeding diatheses,&#xD;
&#xD;
               -  psychiatric illness/social situations that would limit compliance with study&#xD;
                  requirements or compromise the ability of the subject to give written informed&#xD;
                  consent.&#xD;
&#xD;
          -  Clinically significant (i.e., active) cardiovascular disease: cerebral vascular&#xD;
             accident/stroke (&lt; 6 months prior to enrollment), myocardial infarction (&lt; 6 months&#xD;
             prior to enrollment), unstable angina, congestive heart failure (≥ New York Heart&#xD;
             Association Classification Class II), or serious cardiac arrhythmia requiring&#xD;
             medication.&#xD;
&#xD;
          -  Any subject known to have evidence of acute or chronic hepatitis B (positive HBV&#xD;
             surface antigen), hepatitis C (perform HCV RNA if anti-HCV antibody screening test&#xD;
             positive), or human immunodeficiency virus (HIV). Note: testing will be performed if&#xD;
             applicable per physician discretion.&#xD;
&#xD;
          -  Receipt of live attenuated vaccination within 30 days prior to study entry or within&#xD;
             30 days of starting treatment with Avelumab. Note: Seasonal influenza vaccines for&#xD;
             injection are generally inactivated flu vaccines and are allowed; however intranasal&#xD;
             influenza vaccines (e.g., Flu-Mist®) are live attenuated vaccines, and are not&#xD;
             allowed.&#xD;
&#xD;
          -  Female subjects who are pregnant, breast-feeding or male or female patients of&#xD;
             reproductive potential who are not employing an effective method of birth control. For&#xD;
             this study male or female patients of reproductive potential need to employ two highly&#xD;
             effective and acceptable forms of contraception throughout their participation in the&#xD;
             study and for 90 days after last dose of study drug.&#xD;
&#xD;
          -  Any condition that, in the opinion of the investigator, would interfere with&#xD;
             evaluation of study treatment or interpretation of patient safety or study results.&#xD;
&#xD;
          -  Brain metastases or history of leptomeningeal carcinomatosis.&#xD;
&#xD;
          -  Subjects with uncontrolled seizures.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Monika Joshi, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Big Ten Cancer Research Consortium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Univeristy of Iowa Hospital and Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penn State Cancer Intsitute</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.bigtencrc.org</url>
    <description>Big Ten Cancer Research Consortium Website</description>
  </link>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>April 11, 2018</study_first_submitted>
  <study_first_submitted_qc>April 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 19, 2018</study_first_posted>
  <results_first_submitted>June 22, 2020</results_first_submitted>
  <results_first_submitted_qc>June 22, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">July 9, 2020</results_first_posted>
  <last_update_submitted>June 22, 2020</last_update_submitted>
  <last_update_submitted_qc>June 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Big Ten Cancer Research Consortium</investigator_affiliation>
    <investigator_full_name>Monika Joshi, MD</investigator_full_name>
    <investigator_title>Sponsor-Investigator</investigator_title>
  </responsible_party>
  <keyword>Cisplatin-Ineligible</keyword>
  <keyword>Avelumab</keyword>
  <keyword>PD-L1 Monoclonal Antibody</keyword>
  <keyword>Eribulin Mesylate</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Avelumab</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 11, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/81/NCT03502681/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Dose Level 0: Starting Cohort</title>
          <description>Eribulin mesylate: 1.1mg/m2 on days 1,15 Avelumab 10 mg/kg on days 1,15</description>
        </group>
        <group group_id="P2">
          <title>Dose Level 1</title>
          <description>Eribulin mesylate 1.4mg/m2 days 1,15 Avelumab 10mg/kb on days 1,15</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Disease Progression</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Dose Level 0: Starting Cohort</title>
          <description>Eribulin mesylate: 1.1mg/m2 on days 1,15 Avelumab 10 mg/kg on days 1,15</description>
        </group>
        <group group_id="B2">
          <title>Dose Level 1</title>
          <description>Eribulin mesylate 1.4mg/m2 days 1,15 Avelumab 10mg/kb on days 1,15</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
            <count group_id="B2" value="3"/>
            <count group_id="B3" value="6"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71" spread="8.5"/>
                    <measurement group_id="B2" value="69.3" spread="9.1"/>
                    <measurement group_id="B3" value="70.2" spread="7.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Smoking Status</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Never a smoker</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Former smoker</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Histology</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Urothelial(transitional cell) Carcinoma</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Urothelial(transitional cell) Carcinoma, Mixed</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Assess the Adverse Events of Combining Eribulin Mesylate With Avelumab - (MTD Cohort)</title>
        <description>Dose limiting toxicities (DLTs) experienced by subjects while being treated with the combination of eribulin+avelumab, by dose level.</description>
        <time_frame>4-weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dose Level 0: Starting Cohort</title>
            <description>Eribulin mesylate: 1.1mg/m2 on days 1,15 Avelumab 10 mg/kg on days 1,15</description>
          </group>
          <group group_id="O2">
            <title>Dose Level 1</title>
            <description>Eribulin mesylate 1.4mg/m2 days 1,15 Avelumab 10mg/kb on days 1,15</description>
          </group>
        </group_list>
        <measure>
          <title>Assess the Adverse Events of Combining Eribulin Mesylate With Avelumab - (MTD Cohort)</title>
          <description>Dose limiting toxicities (DLTs) experienced by subjects while being treated with the combination of eribulin+avelumab, by dose level.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Neutrophil Count Decreased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Febrile Neutropenia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Assess Response Rates (RR) - (Efficacy Cohort)</title>
        <description>Complete Response (CR) + Partial Response (PR)</description>
        <time_frame>12 months</time_frame>
        <population>Data for this outcome measure was not collected or analyzed due to the early termination of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Dose Level 0: Starting Cohort</title>
            <description>Eribulin mesylate: 1.1mg/m2 on days 1,15 Avelumab 10 mg/kg on days 1,15</description>
          </group>
          <group group_id="O2">
            <title>Dose Level 1</title>
            <description>Eribulin mesylate 1.4mg/m2 days 1,15 Avelumab 10mg/kb on days 1,15</description>
          </group>
        </group_list>
        <measure>
          <title>Assess Response Rates (RR) - (Efficacy Cohort)</title>
          <description>Complete Response (CR) + Partial Response (PR)</description>
          <population>Data for this outcome measure was not collected or analyzed due to the early termination of the study.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assess Disease Control Rate (DCR)</title>
        <description>Complete Response (CR) + Partial Response (PR) + Stable Disease (SD)</description>
        <time_frame>at 3, 6 months</time_frame>
        <population>Data for this outcome measure was not collected or analyzed due to the early termination of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Dose Level 0: Starting Cohort</title>
            <description>Eribulin mesylate: 1.1mg/m2 on days 1,15 Avelumab 10 mg/kg on days 1,15</description>
          </group>
          <group group_id="O2">
            <title>Dose Level 1</title>
            <description>Eribulin mesylate 1.4mg/m2 days 1,15 Avelumab 10mg/kb on days 1,15</description>
          </group>
        </group_list>
        <measure>
          <title>Assess Disease Control Rate (DCR)</title>
          <description>Complete Response (CR) + Partial Response (PR) + Stable Disease (SD)</description>
          <population>Data for this outcome measure was not collected or analyzed due to the early termination of the study.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Estimate Progression Free Survival (PFS)</title>
        <description>probability that a patient remains free of progression of disease by modified RECIST 1.1</description>
        <time_frame>12 months</time_frame>
        <population>Data for this outcome measure was not collected or analyzed due to the early termination of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Dose Level 0: Starting Cohort</title>
            <description>Eribulin mesylate: 1.1mg/m2 on days 1,15 Avelumab 10 mg/kg on days 1,15</description>
          </group>
          <group group_id="O2">
            <title>Dose Level 1</title>
            <description>Eribulin mesylate 1.4mg/m2 days 1,15 Avelumab 10mg/kb on days 1,15</description>
          </group>
        </group_list>
        <measure>
          <title>Estimate Progression Free Survival (PFS)</title>
          <description>probability that a patient remains free of progression of disease by modified RECIST 1.1</description>
          <population>Data for this outcome measure was not collected or analyzed due to the early termination of the study.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Estimate Overall Survival (OS)</title>
        <description>time from start of treatment, Day 1, to the date of death due to any cause</description>
        <time_frame>12 months</time_frame>
        <population>Data for this outcome measure was not collected or analyzed due to the early termination of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Dose Level 0: Starting Cohort</title>
            <description>Eribulin mesylate: 1.1mg/m2 on days 1,15 Avelumab 10 mg/kg on days 1,15</description>
          </group>
          <group group_id="O2">
            <title>Dose Level 1</title>
            <description>Eribulin mesylate 1.4mg/m2 days 1,15 Avelumab 10mg/kb on days 1,15</description>
          </group>
        </group_list>
        <measure>
          <title>Estimate Overall Survival (OS)</title>
          <description>time from start of treatment, Day 1, to the date of death due to any cause</description>
          <population>Data for this outcome measure was not collected or analyzed due to the early termination of the study.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Estimate Median Progression Free Survival (PFS)</title>
        <description>measurement from the date of initiation of avelumab+ eribulin, D1 until the criteria for disease progression is met as defined by modified RECIST 1.1</description>
        <time_frame>12 months</time_frame>
        <population>Data for this outcome measure was not collected or analyzed due to the early termination of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Dose Level 0: Starting Cohort</title>
            <description>Eribulin mesylate: 1.1mg/m2 on days 1,15 Avelumab 10 mg/kg on days 1,15</description>
          </group>
          <group group_id="O2">
            <title>Dose Level 1</title>
            <description>Eribulin mesylate 1.4mg/m2 days 1,15 Avelumab 10mg/kb on days 1,15</description>
          </group>
        </group_list>
        <measure>
          <title>Estimate Median Progression Free Survival (PFS)</title>
          <description>measurement from the date of initiation of avelumab+ eribulin, D1 until the criteria for disease progression is met as defined by modified RECIST 1.1</description>
          <population>Data for this outcome measure was not collected or analyzed due to the early termination of the study.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Estimate Median Overall Survival (OS)</title>
        <description>time from start of treatment, Day 1, that half of the patients in the group with the disease are still alive.</description>
        <time_frame>2.5 years</time_frame>
        <population>Data for this outcome measure was not collected or analyzed due to the early termination of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Dose Level 0: Starting Cohort</title>
            <description>Eribulin mesylate: 1.1mg/m2 on days 1,15 Avelumab 10 mg/kg on days 1,15</description>
          </group>
          <group group_id="O2">
            <title>Dose Level 1</title>
            <description>Eribulin mesylate 1.4mg/m2 days 1,15 Avelumab 10mg/kb on days 1,15</description>
          </group>
        </group_list>
        <measure>
          <title>Estimate Median Overall Survival (OS)</title>
          <description>time from start of treatment, Day 1, that half of the patients in the group with the disease are still alive.</description>
          <population>Data for this outcome measure was not collected or analyzed due to the early termination of the study.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assess the Duration of Response</title>
        <description>the period measured from the time that measurement criteria are met for complete or partial response (whichever status is recorded first) until the date that recurrent or progressive disease is objectively documented.</description>
        <time_frame>2.5 years</time_frame>
        <population>Data for this outcome measure was not collected or analyzed due to the early termination of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Dose Level 0: Starting Cohort</title>
            <description>Eribulin mesylate: 1.1mg/m2 on days 1,15 Avelumab 10 mg/kg on days 1,15</description>
          </group>
          <group group_id="O2">
            <title>Dose Level 1</title>
            <description>Eribulin mesylate 1.4mg/m2 days 1,15 Avelumab 10mg/kb on days 1,15</description>
          </group>
        </group_list>
        <measure>
          <title>Assess the Duration of Response</title>
          <description>the period measured from the time that measurement criteria are met for complete or partial response (whichever status is recorded first) until the date that recurrent or progressive disease is objectively documented.</description>
          <population>Data for this outcome measure was not collected or analyzed due to the early termination of the study.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to six cycles (6 months)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>All Subjects</title>
          <description>All subjects (6) from each dose level.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAEv4</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>FEBRILE NEUTROPENIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>FEVER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>INFECTIONS AND INFESTATIONS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAEv4</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>ANEMIA</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>HYPOTHYROIDISM</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>DIARRHEA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>GASTROESOPHAGEAL REFLUX DISEASE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>CHILLS</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>EDEMA LIMBS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>INFUSION RELATED REACTION</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>INFUSION SITE EXTRAVASATION</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>INFECTIONS AND INFESTATIONS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>KIDNEY INFECTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>NAIL INFECTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>INJURY, POISONING AND PROCEDURAL COMPLICATIONS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>ALANINE AMINOTRANSFERASE INCREASED</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>ASPARTATE AMINOTRANSFERASE INCREASED</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>CREATININE INCREASED</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>LIPASE INCREASED</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>LYMPHOCYTE COUNT DECREASED</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>NEUTROPHIL COUNT DECREASED</sub_title>
                <counts group_id="E1" events="8" subjects_affected="3" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>SERUM AMYLASE INCREASED</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>WHITE BLOOD CELL DECREASED</sub_title>
                <counts group_id="E1" events="8" subjects_affected="2" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERKALEMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>HYPONATREMIA</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ARTHRITIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>BUTTOCK PAIN</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>GENERALIZED MUSCLE WEAKNESS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>MYALGIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>DYSGEUSIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>PARESTHESIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>SINUS PAIN</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>HEMATURIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>ALLERGIC RHINITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>POSTNASAL DRIP</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ALOPECIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>RASH ACNEIFORM</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>RASH MACULO-PAPULAR</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>SKIN AND SUBCUTANEOUS TISSUE DISORDERS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>SURGICAL AND MEDICAL PROCEDURES</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Due to the early termination of the study, no primary or secondary endpoints were analyzed.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Clinicaltrials.gov Results Coordinator</name_or_title>
      <organization>Hoosier Cancer Research Network</organization>
      <phone>317-921-2050</phone>
      <email>jsmith@hoosiercancer.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

